Table 2 Summary of studies analyzing the impact of ART on HPV incidence, persistence and clearance among HIV-infected women
Author | Outcome | Follow-up | Results Comparison and reference groups | Association (95% CI), p value | Conclusion |
|---|---|---|---|---|---|
Lillo et al 2001 | HPV PCR biannually Outcome: Incidence or Persistence (same HPV genotype at enrollment and follow-up) | Median 15.4 months | Incidence: HAART vs. no therapy Persistence: HAART vs. no therapy | OR 0.28 (0.09-0.86), p 0.02 OR 1.18, (0.37-3.77), p 0.77 | HAART protective against new HPV infections No impact of HAART on persistence |
Del Mistro et al 2004 | HPV PCR every 6-12 months Outcome: Persistence and Clearance (undefined) | 49% of N followed for >3 years | No odds ratios discussed | -- | "Prevalence and clearance of HPV not associated with HAART" |
Paramsothy et al 2009 | HPV PCR every 6 months for 10 visits, then annually Outcome: HPV Clearance (2 negative HPV PCR tests at consecutive visits) | Median 2 years for women on HAART; 2.7 years not on HAART | HAART vs. no HAART (adjusted for CD4+ counts) (i) in women with LSIL or HSIL (ii) in women with ASCUS on cytology (iii) in women with normal cytology | (i) HR 4.5 (95% CI: 1.2 16.3) (ii) HR 1.0 (95% CI: 0.4-2.5) (iii) HR 1.7 (95% CI: 0.9-3.1) | HAART promoted clearance of HPV infection in women with LSIL or HSIL on cytology. No impact of HAART on women with ASCUS cytology No impact of HAART on women with normal cytology |